Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD

Executive Summary

Proposed list of topics for review in 2019 by the Institute for Clinical and Economic Review includes a total of 15 drugs but that could change as the year goes on.

You may also be interested in...



J&J Foresees Broad Insurance Coverage For Groundbreaking Spravato Nasal Spray

Datamonitor projects the newly US FDA-approved esketamine product for treatment-resistant depression will reach sales of almost $2bn in the US, Japan and five major European markets.

ICER’s ‘Unsupported Price Increase’ Report Due This Fall

Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.

J&J Seeks A Priority Review For Depression Drug Esketamine

Janssen filed an NDA for esketamine nasal spray for treatment-resistant depression with FDA, which could grant a six-month priority review.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel